Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of July 31, 2012): 5,469,557,879 Ordinary Shares of 25p each.
- Treasury Shares: 479,907,927 Ordinary Shares.
- Total Voting Rights: 4,989,649,952.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share counts as of July 31, 2012, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,989,649,952) to determine notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (479,907,927) when calculating the denominator for ownership interest calculations.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.